Innovation

As leaders in the field of epigenetics, we continue to contribute to the scientific understanding of this important therapeutic space by sharing our findings in peer reviewed publications in leading life science academic journals. We also share our data with the scientific community at global conferences in the form of posters and oral presentations. Highlighted below are some of our recent publications and key articles that continue to build upon the progress of science in this field.

RVX PUBLICATIONS

2017 Publication in American Journal of Cardiovascular Drugs
Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.

2017 Publication in Molecular Pharmacology
RVX-297, a BET bromodomain inhibitor, has therapeutic effects in preclinical models of acute inflammation and autoimmune disease.

2017 Publication in Journal of Cardiovascular Translational Research
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).

2016 Publication in Atherosclerosis
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.

2016 Publication in Metabolism
Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial.

2015 Publication in Expert Opinion on Investigational Drugs
An evaluation of RVX-208 for the treatment of atherosclerosis.

2015 Publication in European Biopharmaceutical Review
New Direction.

2014 Publication in Atherosclerosis
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.

2013 Publication in PLoS One
RVX-208, an Inducer of ApoA-I in Humans, is a BET Bromodomain Antagonist.

RVX POSTERS

2017 American Diabetes Association Scientific Sessions
Apabetalone (RVX-208) Lowers Major Adverse Cardiovascular Events (MACE) in Diabetes Mellitus by Affecting Complement Pathway and Microbiome Activity. 

2017 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress
Effects of Apabetalone (RVX-208) on Serum Albumin in Subjects with CVD, Diabetes and Chronic Kidney Disease; a Post-Hoc Analysis of the ASSURE and SUSTAIN Clinical Trials. 

2017 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress
Apabetalone, A Bromodomain and Extraterminal Protein Inhibitor, Decreases Key Factors in Vascular Calcification in Vitro and in Clinical Trials. 

2017 International Conference on Alzheimer's & Parkinson's Diseases
Apabetalone, a BET Bromodomain Inhibitor, Suppresses Inflammatory Mediators in Microglia that Contribute to Neurodegenerative Disease.

2017 Atherosclerosis, Thrombosis & Vascular Biology Scientific Sessions
Apabetalone (RVX-208), a Selective CET Protein Inhibitor, Reduces Expression of Acute Phase Response Markers in Vitro and In Patients with Cardiovascular Disease and Chronic Kidney Disease.

2016 American Society of Nephrology Conference
Apabetalone Reduces Levels of Key Markers Involved in Vascular Calcification. 

2016 American Heart Association Scientific Sessions
Apabetalone (RVX-208) Reduces Expression of Acute Phase Response Markers in Vitro and in Patients with Cardiovascular Disease.

2016 European Society of Cardiology Congress
Modulation of the Complement Cascade in Cardiovascular Disease Patients by a Bromodomain and Extraterminal (BET) Protein Inhibitor. 

2016 Atherosclerosis, Thrombosis & Vascular Biology Scientific Sessions
Apabetalone (RVX-208) has Anti-Atherosclerotic, Anti-Thrombotic and Anti-Inflammatory Effects in Patients with Cardiovascular Disease. 

2015 American Heart Association Scientific Sessions
RVX-208, a Selective Bromodomain Extra-Terminal (BET) Protein Inhibitor, Acts on Several Pathways to Benefit Cardiovascular Risk. 

2015 American Society of Nephrology Conference
Alkaline Phosphatase Lowering by Selective BET Inhibition, a Novel Mechanism for MACE Reduction in High Risk CVD, Diabetes and CKD Patients; a Post-hoc Analysis of Phase 2b Studies with Apabetalone (RVX-208).

2015 American Society of Nephrology Conference
Apabetalone (RVX-208), a First-in-Class Epigenetic BET Inhibitor, has Effects on ALP and eGFR in Subjects with CVD and CKD; a Post-hoc Analysis of ASSERT, SUSTAIN and ASSURE Clinical Trials.

LANDMARK STUDIES

Haarhaus et al. 2017 
Alkaline Phosphatase: A Novel Treatment Target For Cardiovascular Disease in CKD

Ridker et al. 2017
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Campbell et al. 2017
BET Bromodomain Inhibitors and Agonists of the Beta-2 Adrenergic Receptor Identified in Screens for Compounds That Inhibit DUX4 Expression in FSHD Muscle Cells

Hwang et al. 2017
NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease

Hill et al. 2017
Paroxysmal Nocturnal Haemoglobinuria

Najafova et al. 2017
BRD4 Localization to Lineage-Specific Enhancers is Associated with a Distinct Transcription Factor Repertoire

Suarez-Alvarez et al. 2016
Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage

Xiong et al. 2016
Pharmacological Targeting of BET Proteins Inhibits Renal Fibroblast Activation and Alleviates Renal Fibrosis

Hollander et al. 2015
Gender-Specific Plasma Proteomic Biomarkers in Patients with Anderson–Fabry Disease

Meloche et al. 2015
Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension

Patel el al. 2014
BET Bromodomain Inhibition Triggers Apoptosis of NF1-Associated Malignant Peripheral Nerve Sheath Tumors through Bim Induction

White et al. 2013
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
 
Mottillo et al. 2010
The Metabolic Syndrome and Cardiovascular Risk
 
Tonelli et al. 2009
Relation Between Alkaline Phosphatase, Serum Phosphate, and All-Cause or Cardiovascular Mortality

Blayney et al. 2008
High Alkaline Phosphatase Levels in Hemodialysis Patients are Associated with Higher Risk of Hospitalization and Death
 
Barter et al. 2007
HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
 
Walldius et al. 2001
High Apolipoprotein B, Low Apolipoprotein A-I, and Improvement in the Prediction of Fatal Myocardial Infarction (AMORIS study): A Prospective Study